Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Bristol-Myers Squibb (BMY) CEO Christopher Boerner, speaking at the Morgan Stanley Global Healthcare Conference on September 8, 2025, addressed the company's known loss of exclusivity (LOE) exposure. He outlined a strategic approach to drive growth into the latter half of the decade, emphasizing the critical role of current product performance. Boerner highlighted consistent commercial execution and strong recent growth, signaling progress in mitigating the impact of patent expirations.

Analysis

Bristol-Myers Squibb's (BMY) senior leadership is actively managing the narrative around its significant, and widely known, loss of exclusivity (LOE) exposure. At the Morgan Stanley Global Healthcare Conference, CEO Christopher Boerner confirmed a three-part strategy designed to navigate this patent cliff, emphasizing that the first component is maximizing the growth of its current on-market products to drive performance into the late 2020s. Management's commentary, which carried an optimistic tone and a positive sentiment score of 0.5 for BMY, highlighted a track record of "consistent performance" and "very good growth" in the most recent period. This communication signals a concerted effort to shift investor focus from the impending revenue gap towards the tangible results being delivered by the current commercial organization, thereby building confidence in the company's ability to offset future LOE impacts.

Key Decisions for Investors

• Investors should scrutinize upcoming quarterly earnings reports to validate management's claims of 'consistent performance' and 'very good growth' in the in-line portfolio, as this is positioned as the primary driver to offset LOE pressures.
• While management's commentary is positive, the LOE headwind remains a significant long-term risk, so it is crucial to evaluate whether the current growth trajectory is substantial enough to bridge the eventual revenue cliff.
• Given the strategic focus on commercial execution, investors should monitor sales momentum and market share trends for BMY's key growth assets as the most direct measure of the strategy's success.